Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,473,377 papers from all fields of science
Search
Sign In
Create Free Account
ME-344
Known as:
mTOR1/2 Kinase Inhibitor ME-344
An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Isoflavones
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract OT2-07-02: CNIO-BR-009 trial: Targeting mitochondrial metabolism with ME-344 in breast cancer upon bevacizumab-induced vascular normalization: A phase 0 randomized clinical trial
A. Cortés
,
J. V. Apala
,
+7 authors
M. Quintela-Fandino
2018
Corpus ID: 79621963
Background: Antiangiogenic agents have shown activity in breast cancer; however their use should be optimized. One potential…
Expand
2013
2013
ME-344, a Novel Isoflavone with Activity as a Mitochondrial Oxygenase Inhibitor
Y. Manevich
,
M. Quintela-Fandino
,
P. Navarro
,
Tew Kd
,
Townsend Dm
2013
Corpus ID: 85894514
ME-344, a second-generation derivative of a natural product isoflavone is being developed as a clinical candidate in small cell…
Expand
2013
2013
Abstract 2457: Ex vivo analysis of novel isoflavanoids (ME-143 and ME-334) in patient derived triple negative breast cancer tumors.
K. Praveen
,
Thomas B. Broudy
,
Cyrus Mirsaidi
,
O. Moreno
,
D. Gold
2013
Corpus ID: 76459172
There is an unmet need for novel effective therapeutics to treat triple negative (ER, PR and Her2 negative) breast cancer in…
Expand